Identify the optimal pharmacological management for each distinct presentation of lower genital tract infection by pairing the clinical findings with the correct therapeutic approach.
- Profuse, homogeneous, thin grayish vaginal discharge; pH 5.5; wet mount shows stippled epithelial cells with obscured margins.Oral metronidazole for the patient; no partner treatment required
- Intense vulvar pruritus with thick, curd-like vaginal discharge; pH 4.2; microscopy reveals budding organisms with elongated structures.Oral fluconazole for the patient; no partner treatment required
- Yellow-green frothy vaginal discharge with cervical punctate hemorrhages; pH 6.0; wet mount shows motile, flagellated organisms.Oral metronidazole for the patient; concurrent partner treatment required
- Endocervical mucopurulent discharge and a friable cervix; vaginal pH 4.0; wet mount shows abundant leukocytes but no distinct organisms.Intramuscular ceftriaxone and oral doxycycline for the patient; concurrent partner treatment required
Answer
Bacterial vaginosis requires metronidazole for the patient only. Vulvovaginal candidiasis requires fluconazole for the patient only. Trichomoniasis requires metronidazole for both the patient and their partner. Mucopurulent cervicitis is managed empirically with ceftriaxone and doxycycline for the patient and their partner.
Appropriate management of vaginitis and cervicitis requires correlating clinical signs and microscopic findings with the specific pathogen. A critical management decision is determining whether the condition is a sexually transmitted infection requiring concurrent partner treatment (trichomoniasis, cervicitis), or an alteration of normal flora where partner treatment does not reduce recurrence rates (bacterial vaginosis, candidiasis).
Step-by-Step Solution
Key Concept
Diagnosis and management of common lower genital tract infections, including indications for sexual partner treatment.
Estimated Time:1m 30s